Posting this under the heading it deserves: Historical amylin analogues and what happened to them Everything below is what sits behind that.
Proposing that historical amylin analogues deserves a maintained page rather than a recurring topic, and drafting the skeleton here so that the argument about scope happens before the writing rather than after.
What I think belongs on it, what does not, and the three claims that would need a citation each.
Where I part company with the opening post, and it is a narrow parting.
Cagrilintide is a long-acting amylin analogue, which puts it in a different mechanistic family from the incretin agonists it is usually discussed alongside. Amylin signalling contributes to satiety through a distinct pathway.
That holds under the stated conditions and I have stated them.
The arithmetic in the opening post is right; the assumption feeding it is the part to check.
A note on how historical amylin analogues gets discussed rather than on historical amylin analogues itself: the confident posts get the replies and the careful ones get ignored, and the careful ones have been right more often.
Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.
Building on post #4 rather than restating it.
What is genuinely unknown about long-term amylin agonism: real-world response rates, whether effect is durable with continued use, whether satiety adaptation occurs over months or years, safety profile in populations not enrolled in the trials.
Post #2 put the caveat in the right place and I want to underline it.
Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a difficult tolerability profile. A weekly formulation is a substantially different proposition and data from that is more relevant than data from pramlintide.
Checked the historical amylin analogues claim against the primary source this morning. It survives, with a narrower scope than the version quoted here. Posting the narrower scope.
Quietly grateful for the plain phrasing. Not every thread gets that.
Taking post #7 at face value and following it one step further.
On historical amylin analogues I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.
Anyone submitting this for independent testing should say in the submission that it is an amylin analogue rather than an incretin. Method selection differs and a default incretin gradient is not necessarily the right one.
I am not the right person to answer the follow-up to this.
Post #9 describes the usual case. This is about the unusual one.
Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly formulation addresses that practical barrier.
Noting that the question and the thing people usually mean by it are different.
Adding the measurement that post #9 says would settle it.
Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.
Where the historical amylin analogues discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the same sentence with different clothes on.
Answering the question post #13 raises rather than the one it answers.
Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate nausea or is tolerable is a question phase 3 exists to answer.
Worth stating the null on historical amylin analogues before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one.
Post #17 is the version of this I will quote in future. One addition.
On analysis: an amylin analogue and its aggregates are not equally detectable by a standard reversed-phase method, because a large aggregate may not elute at all. Area percent cannot see what stays on the column.
Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.
The literature is thinner on this than the confidence in the thread implies.
Native amylin has awkward physical properties — it aggregates readily, which is why a stable analogue is a pharmaceutical achievement rather than a formulation detail.
If this contradicts something upthread, the upthread version may well be the better one.
On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.
The evidence for this is thinner than the way I have phrased it suggests.
Historical amylin analogues: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I would like to know which.
Amylin analogues affect gastric emptying as well, so the mechanism overlaps the incretins in at least one place. That overlap is part of why the combination's tolerability profile is not simply the sum of the two.
If that reads as pedantic, it is, and it has saved me twice.
Coming back to post #20, because the follow-up matters more than the original answer.
Comparing an amylin analogue to an incretin agonist on weight change alone misses that they were developed to be used together rather than instead of each other.
What is genuinely unknown about long-term amylin agonism: real-world response rates, whether effect is durable with continued use, whether satiety adaptation occurs over months or years, safety profile in populations not enrolled in the trials.
If it helps: the failure mode here is usually boring rather than dramatic.
Confirming post #25 from a second method, which matters more than confirming it from a second person.
Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.
I had written a reply contradicting post #24 and deleted it. Here is what survived.
Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate nausea or is tolerable is a question phase 3 exists to answer.
Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a difficult tolerability profile. A weekly formulation is a substantially different proposition and data from that is more relevant than data from pramlintide.
Post #28 and I disagree about the size of the effect, not about the direction.
Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.